198 related articles for article (PubMed ID: 14760171)
41. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Sawhney N; Moses JW; Leon MB; Kuntz RE; Popma JJ; Bachinsky W; Bass T; DeMaio S; Fry E; Holmes DR; Teirstein PS
Circulation; 2004 Jul; 110(4):374-9. PubMed ID: 15249503
[TBL] [Abstract][Full Text] [Related]
42. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
[TBL] [Abstract][Full Text] [Related]
43. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
[TBL] [Abstract][Full Text] [Related]
44. Coronary bifurcation stenting. Current techniques, outcome and possible future developments.
Melikian N; Airoldi F; Di Mario C
Minerva Cardioangiol; 2004 Oct; 52(5):365-78. PubMed ID: 15514572
[TBL] [Abstract][Full Text] [Related]
45. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
46. Late incomplete lesion coverage following Cypher stent deployment for diffuse right coronary artery stenosis.
Halkin A; Carlier S; Leon MB
Heart; 2004 Aug; 90(8):e45. PubMed ID: 15253987
[TBL] [Abstract][Full Text] [Related]
47. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
[TBL] [Abstract][Full Text] [Related]
48. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials.
Halkin A; Stone GW
J Interv Cardiol; 2004 Oct; 17(5):271-82. PubMed ID: 15491330
[TBL] [Abstract][Full Text] [Related]
49. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
50. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
[TBL] [Abstract][Full Text] [Related]
51. Polymer-based paclitaxel-eluting coronary stents. Clinical results in de novo lesions.
Chieffo A; Colombo A
Herz; 2004 Mar; 29(2):147-51. PubMed ID: 15054587
[TBL] [Abstract][Full Text] [Related]
52. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
[TBL] [Abstract][Full Text] [Related]
53. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
[TBL] [Abstract][Full Text] [Related]
54. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
55. Drug-eluting versus bare-metal coronary stents: where are we now?
Amoroso NS; Bangalore S
J Comp Eff Res; 2012 Nov; 1(6):501-8. PubMed ID: 24236469
[TBL] [Abstract][Full Text] [Related]
56. Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting.
Lemos PA; Mercado N; van Domburg RT; Kuntz RE; O'Neill WW; Serruys PW
Circulation; 2004 Nov; 110(20):3199-205. PubMed ID: 15505082
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials.
Stettler C; Allemann S; Egger M; Windecker S; Meier B; Diem P
Heart; 2006 May; 92(5):650-7. PubMed ID: 16251229
[TBL] [Abstract][Full Text] [Related]
58. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions.
Waugh J; Wagstaff AJ
Am J Cardiovasc Drugs; 2004; 4(4):257-68. PubMed ID: 15285700
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
[TBL] [Abstract][Full Text] [Related]
60. Hybrid coronary revascularization in the era of drug-eluting stents.
Murphy GJ; Bryan AJ; Angelini GD
Ann Thorac Surg; 2004 Nov; 78(5):1861-7. PubMed ID: 15511503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
